Biotech | 08 December 2021
SPARC partners with Visiox for ophthalmic drugs
SPARC will be eligible to receive an upfront payment, milestone payments and royalty on sales, in addition to 10% equity in Visiox
SPARC will be eligible to receive an upfront payment, milestone payments and royalty on sales, in addition to 10% equity in Visiox
The investigational compound, GZR18, is a novel analogue of glucagon-like peptide-1 (GLP-1), an incretin hormone responsible for many glucoregulatory effects
The facility will supply clinical trial materials for the development of vaccines and biologics up to Phase II stage and is expected to be fully operational by early 2023.
It works with Pfizer to support more rapid innovation and improved clinical manufacturing operations to help develop tomorrow’s therapies
SPARC will pay Biomodifying a percentage of payments received for sublicenses of the licensed IP
The company has also started working with a large pharma company on the API supply of a recently launched animal and human health product
Soft-mist inhalation (SMI) technology allows for delivery of inhalation drugs from a small, portable hand-held inhaler device without the use of propellants
Preclinical data demonstrate sotrovimab, authorised in multiple countries around the world, retains activity against all tested variants of concern, including key mutations of Omicron
Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program demonstrating superior efficacy of deucravacitinib over Otezla (apremilast)
ALASTIN’s patented, differentiated technology and products are highly synergistic with Galderma’s premium portfolio
Growing CRISPR genome editing portfolio supports researchers on path to future therapeutic applications
.jpg)
Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab
Merck has shared these additional analyses with the FDA and they will be presented to the FDA’s Antimicrobial Drugs Advisory Committee on Nov. 30th
The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease
This agreement marks a milestone for Baidu to use its strengths in computational biology to optimize mRNA vaccine and therapy designs
Owkin builds best-in-class predictive biomedical AI models and robust data sets
The partnership will help advance GreenLight's messenger RNA Covid-19 vaccine candidate
Arrowhead to receive US $ 120 million upfront payment for Phase 1/2 program for NASH and is eligible to receive potential milestone payments and royalties on commercial sales
GreenLight Biosciences is a Boston-based biotechnology company dedicated to making ribonucleic acid (RNA) products affordable and accessible
State-of-the-art R&D facility designed to foster collaboration across world-class science ecosystem
Subscribe To Our Newsletter & Stay Updated
